STOCK TITAN

Abeona (ABEO) Rule 144 Notice: Insider Discloses 17,376-Share Sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Abeona Therapeutics (ABEO) Form 144 shows a proposed sale of 17,376 shares of common stock through Stifel Nicolaus & Company on 09/22/2025 with an aggregate market value of $101,749. The filing lists total shares outstanding of 51,156,736, so the proposed sale equals a small fraction of the outstanding float. The notice records an acquisition of 1,360 shares as Restricted Stock Units on 09/21/2025 with cash payment on 09/22/2025. It also discloses a sale by Brendan O'Malley of 17,428 shares on 07/09/2025 for gross proceeds of $102,053. The filer attests there is no undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sale disclosed; transaction size is immaterial relative to outstanding shares, so market impact is likely limited.

The Form 144 reports a proposed sale of 17,376 shares valued at $101,749 against 51,156,736 shares outstanding, representing roughly 0.034% of outstanding shares. That scale suggests limited market impact from this single proposed transaction. The filing also documents a recent restricted stock unit vesting (1,360 shares) and a prior sale by Brendan O'Malley (17,428 shares) in July generating $102,053. From a trading-volume and dilution perspective, these amounts are small. The filing fulfills Rule 144 notice requirements and provides transparent disclosure of the insider activity.

TL;DR: Form 144 indicates insider compliance with disclosure rules; recurring insider sales warrant monitoring but are not materially large here.

The document is a routine Rule 144 notice showing proposed and recent insider sales and an RSU acquisition. The signer’s representation that no material nonpublic information is known is standard language on this form. While insider sales can inform governance and confidence discussions, the magnitude reported—both the planned 17,376-share sale and the July 9 sale of 17,428 shares—are small relative to total shares outstanding, reducing immediate governance concern. Continued patterns of sales or larger dispositions would be more material.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ABEO Form 144 disclose about proposed insider sales?

The filing reports a proposed sale of 17,376 common shares through Stifel Nicolaus on 09/22/2025 with an aggregate market value of $101,749.

How large is the proposed sale relative to Abeona's outstanding shares (ABEO)?

The filing lists 51,156,736 shares outstanding, so the proposed sale (~17,376 shares) represents roughly 0.034% of outstanding shares.

Did the filer recently acquire any shares before this proposed sale?

Yes. The filer acquired 1,360 shares as Restricted Stock Units on 09/21/2025, with payment recorded on 09/22/2025.

Were there other recent sales by related persons disclosed?

The filing shows Brendan O'Malley sold 17,428 shares on 07/09/2025 for gross proceeds of $102,053.

Does the Form 144 include any statement about undisclosed material information?

Yes. The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Abeona Therapeut

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

281.25M
48.61M
5.78%
73.58%
17.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND